Efficacy and Safety of Intravenous Secukinumab in Noninfectious Uveitis Requiring Steroid-Sparing Immunosuppressive Therapy

Ophthalmology

Volumn 122, Issue 5, 2015, Pages 939-948

  Letko, Erik ^a   Yeh, Steven ^b   Stephen Foster, C ^c,d,e   Pleyer, Uwe ^f   Brigell, Mitchell ^g   Grosskreutz, Cynthia L ^g  

^a Corneal Consultants of Colorado ^*  (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^d Massachusetts Eye Research and Surgery Institute   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISOLONE ACETATE; PREDNISONE; SECUKINUMAB; GLUCOCORTICOID; IL17A PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTERIOR EYE CHAMBER; ANXIETY; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRY EYE; EYE PAIN; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; MALE; MULTICENTER STUDY; MYCOSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SIDE EFFECT; TENSION HEADACHE; TREATMENT RESPONSE; URINARY TRACT INFECTION; UVEITIS; VISUAL ACUITY; VITREOUS BODY; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; EYE DISEASES; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; DOUBLE-BLIND METHOD; EYE DISEASES; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-17; MALE; MIDDLE AGED; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VITREOUS BODY; YOUNG ADULT;

EID: 84928829789     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.12.033     Document Type: Article

References (29)

1. R.B. Nussenblatt The natural history of uveitis Int Ophthalmol 14 1990 303 308
2. O.M. Durrani, N.N. Tehrani, and J.E. Marr Degree, duration, and causes of visual loss in uveitis Br J Ophthalmol 88 2004 1159 1162
3. M.D. de Smet, S.R. Taylor, and B. Bodaghi Understanding uveitis: the impact of research on visual outcomes Prog Retin Eye Res 30 2011 452 470
4. D.C. Gritz, and I.G. Wong Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study Ophthalmology 111 2004 491 500
5. N.R. Acharya, V.M. Tham, and E. Esterberg Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study JAMA Ophthalmol 131 2013 1405 1412
6. E.B. Suhler, M.J. Lloyd, and D. Choi Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest Am J Ophthalmol 146 2008 890 896.e8
7. R.W. Lee, and A.D. Dick Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation Eye (Lond) 26 2012 17 28
8. J. Kruh, and C.S. Foster Corticosteroid-sparing agents: conventional systemic immunosuppressants Dev Ophthalmol 51 2012 29 46
9. O. Tomkins-Netzer, S.R. Taylor, and S. Lightman Corticosteroid-sparing agents: new treatment options Dev Ophthalmol 51 2012 47 56
10. F. Willermain, J.T. Rosenbaum, and B. Bodaghi Interplay between innate and adaptive immunity in the development of non-infectious uveitis Prog Retin Eye Res 31 2012 182 194
11. P. Miossec, and J.K. Kolls Targeting Il-17 and Th17 cells in chronic inflammation Nat Rev Drug Discov 11 2012 763 776
12. A. Amadi-Obi, C.R. Yu, and X. Liu TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1 Nat Med 13 2007 711 718
13. K. Hamzaoui, A. Hamzaoui, and F. Guemira Cytokine profile in Behçet's disease patients: relationship with disease activity Scand J Rheumatol 31 2002 205 210
14. W. Chi, X. Zhu, and P. Yang Upregulated IL-23 and IL-17 in Behçet patients with active uveitis Invest Ophthalmol Vis Sci 49 2008 3058 3064
15. S. Sugita, Y. Kawazoe, and A. Imai Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease Arthritis Res Ther 14 2012 R99
16. Y. Peng, G. Han, and H. Shao Characterization of IL-17+ interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis Invest Ophthalmol Vis Sci 48 2007 4153 4161
17. R. Zhang, J. Qian, and J. Guo Suppression of experimental autoimmune uveoretinitis by anti-IL-17 antibody Curr Eye Res 34 2009 297 303
18. Z. Zhang, W. Zhong, and D. Spencer Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11.10 mice Cytokine 46 2009 79 91
19. W. Hueber, D.D. Patel, and T. Dryja Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis Sci Transl Med 2 2010 52ra72
20. A.D. Dick, I. Tugal-Tutkun, and S. Foster Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials Ophthalmology 120 2013 777 787
21. J.E. Thorne, D.A. Jabs, and F.A. Qazi Mycophenolate mofetil therapy for inflammatory eye disease Ophthalmology 112 2005 1472 1477
22. S. Gangaputra, C.W. Newcomb, and T.L. Liesegang Methotrexate for ocular inflammatory disease Ophthalmology 116 2009 2188 2198
23. M. Kopf, M.F. Bachmann, and B.J. Marsland Averting inflammation by targeting the cytokine environment Nat Rev Drug Discov 9 2010 703 718
24. M. Cordero-Coma, T. Yilmaz, and S. Onal Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis Ocul Immunol Inflamm 21 2013 19 27
25. J.N. Martel, E. Esterberg, A. Nagpal, and N.R. Acharya Infliximab and adalimumab for uveitis Ocul Immunol Inflamm 20 2012 18 26
26. S. Yeh, K. Wroblewski, and R. Buggage High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis J Autoimmun 31 2008 91 97
27. R.B. Nussenblatt, E. Fortin, and R. Schiffman Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial Proc Natl Acad Sci U S A 96 1999 7462 7466
28. R.B. Nussenblatt, J.S. Peterson, and C.S. Foster Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series Ophthalmology 112 2005 764 770
29. G. Van Assche, S. Vermeire, and V. Ballet Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial Gut 61 2012 229 234